BELIMUMAB (Benlysta) is a targeted, human monoclonal antibody that binds to soluble B lymphocyte stimulator (BLyS). Benlysta does not bind to B cells directly. By binding BLyS, Benlysta allows more B cells to undergo the normally occurring process of apoptosis, which inhibits the survival of B cells, including autoreactive B cells and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. Show
Benlysta is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus who are receiving standard therapy. Limitations of Use: The efficacy of Benlysta has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Benlysta has not been studied in combination with other biologics or intravenous cyclophosphamide. Use of Benlysta is not recommended in these situations. Resources from ManufacturerPatient Medication Guide FDA-Approved Indications and DosingBenlysta is indicated for the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy. Dosing
ContraindicationsBenlysta is contraindicated in patients who have had anaphylaxis with belimumab. Warnings and Precautions
Common Adverse Effects after Administration of Benlysta
Rare Adverse Effects after Administration of Benlysta
Pre-Infusion Checklist
(If the answer is yes to any of these questions, review with ordering provider.)
Medication PreparationBenlysta is provided as a lyophilized powder in a single-use vial for intravenous infusion only and should be reconstituted and diluted by a healthcare professional using aseptic technique as follows: use of a 21 to 25-gauge needle is recommended when piercing the vial stopper for reconstitution and dilution. Reconstitution Instructions
Medication Administration and Monitoring
Vital Signs Monitoring Review Orders and Obtain IV Access*Do not reconstitute Benlysta vials until after obtaining intravenous access* Prior to dosing with Benlysta, the provider should consider administering premedication for prophylaxis against infusion reactions and hypersensitivity reactions. The infusion nurse should check for pre-medication orders. Managing Infusion ReactionsAcute infusion reaction can occur during the administration of this agent. Patients may also have an infusion reaction the following day after the infusion. Anaphylactoid and anaphylaxis reactions can result. If patient reports mild reactions (such as dizziness, hives, flushing, chills, etc.), slow down the infusion rate and assess patient. For more severe reactions (such as difficulty breathing, chest pain, high or low blood pressure, swelling of face and hands, fever, chills or anaphylaxis) or where mild reactions persist, stop the infusion and treat the acute reaction. Notify the supervising provider immediately to coordinate next plan of action. Patients should be informed that infusion reactions can be delayed, and should contact their provider at the first sign of an allergic reaction which may include:
Additional ConsiderationsPerioperative Management of Medications Used in the Treatment of Rheumatoid Arthritis Updated February 2020 - ARP Practice Committee Disclaimer What type of allergic reaction is rheumatoid arthritis?Interstitial granulomatous dermatitis is another rash that can occur with rheumatoid arthritis. Doctors may also call this condition rheumatoid papules. Symptoms associated with the condition include red plaques or bumps that closely resemble eczema. The rash is itchy and often painful.
What type of immune response is RA?Rheumatoid arthritis, or RA, is an autoimmune and inflammatory disease, which means that your immune system attacks healthy cells in your body by mistake, causing inflammation (painful swelling) in the affected parts of the body. RA mainly attacks the joints, usually many joints at once.
What is the most common physical manifestation in a patient with rheumatoid arthritis?Rheumatoid nodules are the most frequent skin manifestations (20%) in RA. They occur mainly in rheumatoid factor positive RA patients and in early RA give risk to severe extra-articular manifestations.
Which is a priority nursing diagnosis for a patient with rheumatoid arthritis?The most common issues that should be addressed in the nursing care plan for the patient with rheumatoid arthritis (RA) include pain, sleep disturbance, fatigue, altered mood, and limited mobility.
|